BIOHLDG 0179 Share Price
RM0.22
52 Weeks Range : 0.18 - 0.375
4.0/10
(Expert Score)
Product is rated as #66 in category ACE Market
PROS:
- Positive Cash Company
- Very Low Gearing
- Very High Trading Value
CONS:
- Poor Income Near Future
- Very Low Price-to-Tangible
klse: Bioalpha Holdings Bhd
Corporate Information
Board : Ace
Shariah : Shariah Compliant
Sector : Construction Ringgit Consumer
Address: No 10, Jalan P/9A, Seksyen 13, Bandar Baru Bangi, Bangi, 43650, Selangor
Contact: +603-89251222
Website: https://www.bioa.com.my/
Corporate Background
Bioalpha Holdings Berhad manufactures and sells health supplement products. The Company offers health supplement products such as processed herbs, formulated ingredients, and functional foods, as well as herbal and non-herbal supplements. Bioalpha Holdings serves customers in Malaysia.
Genaral Info: BIOHLDG 0179
|
Result
Quarter Report History
| Date | Revenue,k | PBT,k | Net Profit,k |
|---|---|---|---|
| 27/05/21 | 24,783 | 1,549 | 1,498 |
| 02/03/21 | 16,721 | -14,112 | -13,985 |
| 27/11/20 | 6,871 | -10,441 | -9,709 |
| 28/08/20 | 6,392 | -8,199 | -7,932 |
| 25/06/20 | 6,532 | -5,305 | -5,503 |
| 28/02/20 | 18,413 | 3,945 | 3,033 |
| 28/11/19 | 17,276 | 3,516 | 3,105 |
| 30/08/19 | 14,033 | 2,035 | 2,034 |
| 27/05/19 | 12,482 | 1,266 | 858 |
| 28/02/19 | 17,313 | 5,287 | 3,020 |
| 26/11/18 | 20,182 | 4,407 | 4,199 |
| 23/08/18 | 19,546 | 4,086 | 4,141 |
Fundamental
Fundamental Analysis
| Last 4 Quarter Revenue (RM’000) | 54,767 |
|---|---|
| Last 4 Quarter Net Profit (RM’000) | -31,876 |
| Last 4 Quarter EPS (sen) | -2.97 |
| Last 4 Quarter PER | – |
| Last 4 Quarter Dividend (sen) | – |
| Last 4 Quarter Dividend Yield (%) | – |
| Net Tangible Assets (RM) | 0.15 |
| Goodwill (RM) | 53,630 |
| Cash (RM’000) | 27,610 |
| Debt (RM’000) | 12,270 |
| Total Debt (RM’000) | 27,500 |
| Net Assets (RM’000) | 164,000 |
| Current Ratio | 7.42 |
| Quick Ratio | 6.63 |
| Cash Ratio | 2.75 |
Technical
Technical Analysis
| MACD (26 vs 12) | 0.003 |
|---|---|
| Exponential Moving Average 5 | 0.214 |
| Exponential Moving Average 20 | 0.205 |
| Exponential Moving Average 90 | 0.213 |
| Relative Strength Index 14 | 0.71 |
| Stochastic %D 3 | 0.67 |
| Stochastic %K 14 | 0.70 |
8 reviews for BIOHLDG 0179
Show all
Most Helpful
Highest Rating
Lowest Rating
The Edge –
Bioalpha Holdings Bhd announced that it has entered into a two-year procurement and distribution agreement with Shanghai Bukun Trading Co Ltd for the procurement and distribution of vaccines in Malaysia, which include the Covid-19 vaccine developed by Sinovac Biotech Co Ltd, subject to approval by the relevant authorities, including the Ministry of Health (MoH) and the National Pharmaceutical Regulatory Agency (NPRA).
The Edge –
Bioalpha Holdings Bhd has been appointed by Hong Kong-listed Ritamix Global Ltd as a contract manufacturer to make and supply a longevity dietary supplement. They are expecting multi-millions of orders from Ritamix for the Malaysia and China markets. The supplement product contains the nicotinamide mononucleotide (NMN) compound that can help restore energy and reduce typical signs of ageing such as gradual weight gain. Managing director William Hon said he expects NMN products to deliver a gross profit margin of 50% based on the selling price to Ritamix.
The Edge –
Integrated health supplement company Bioalpha Holdings Bhd has proposed a private placement exercise which is estimated to raise up to RM13.77 million. It plans to issue up to 59.86 million new ordinary shares, representing not more than 5% of its enlarged share capital, to raise money for working capital. Assuming full subscription of the placement shares at an indicative price of 23 sen each, the company would raise up to RM13.77 million, Bioalpha said in a filing with Bursa Malaysia today.
The Edge –
Bioalpha Holdings Bhd, which in July signed a RM2.1 billion contract to supply health food to China, recorded sales of over RM1 million from its first delivery made in September. The delivery comprised health food ingredients for the preparation of health food and nutritional meals to be distributed to customers in Guizhou province, the company said in a statement today. The supply contract is valued at 700 million yuan (RM427 million) annually for a duration of five years, subject to annual renewal. This translates into a potential contract value of up to 3.5 billion yuan (RM2.1 billion) over the five-year period.
BURSA MALAYSIA –
The revenue for the Q2 2020 decreased by RM0.14 million or 2.14% to RM6.39 million from RM6.53 million in Q1 2020, due to the adverse impact brought by the COVID19 pandemic and the resultant MCO.
REMUNERATION STUDY –
In Financial Year End 2019, the directors’ remuneration was 2.43 million. It was slightly high compared to average in listed companies, considering the employees’ remuneration of 7.3 million and auditor’s remuneration of 203 thousands
BURSA MALAYSIA –
The revenue for the first (1st) quarter ended 31 March 2020 decreased by RM11.88 million or 6.54% to RM6.53 million from RM18.41 million in the fourth (4th) quarter ended 31 December 2019, due to seasonality factor that was further exacerbated by the COVID-19 pandemic and the resultant MCO. The Group’s business activities are subject to seasonal trends where the first (1st) quarter performance is usually the softest due to fewer working days as a result of festive holidays.
Investing Malaysia –
Average investing volume for Bioalpha Holdings Bhd in the past three months in stock market was 1998.9k lots
Investing Malaysia –
BIOHLDG gets a score of 25.05 in our equity and assets quality test based on current share price of RM0.165
Investing Malaysia –
Bioalpha Holdings Bhd gets a score of 22.36 in our stability test after the balance sheet, money statement study
Investing Malaysia –
Stock code of 0179 in Bursa Malaysia declared adjusted 0.26% dividend yield in past few years
Investing Malaysia –
BIOHLDG is estimated to have a profit consensus of 15.72 millions, with an adjusted market capitalization of 144.09 millions
REMUNERATION STUDY –
In Financial Year End 2018, the directors’ remuneration was 2.33 million. It was slightly high compared to average in listed companies, considering the employees’ remuneration of 7.8 million and auditor’s remuneration of 162 thousands